Citations

Clear

3138 citation(s) found for "Smith, AM".

Expanding the Dynamic Range of Fluorescence Assays through Single-Molecule Counting and Intensity Calibration
Smith, Lucas D. , Smith, Andrew M. , Kohli, Manish , Smith, A M

Mayo Clinic

Journal of the American Chemical Society | September 14, 2018 | Volume: 140 | Issue: 42 | Pages: 13904-13912

10.1021/jacs.8b08879 | PMID 30215524 Get It

Long-term Immunosuppression Adherence After Kidney Transplant and Relationship to Allograft Histology
Lorenz, Elizabeth C. , Cosio, Fernando G., Shah, Nilay D. , Groehler, Paul N., Verdick, Jayson S., Park, Walter D. , Stegall, Mark D. , Stegall, Mark D , Park, Walter , Smith, Byron H. , Schinstock, Carrie A.

Mayo Clinic

Transplantation Direct | September 8, 2018 | Volume: 4 | Issue: 10 | Pages: e392

10.1097/txd.0000000000000824 | PMID 30498769 Get It

Background Nonadherence to immunosuppression after kidney transplant is an important contributor to graft failure. Little is known about how nonadherence changes 3 years posttransplant when Medicare coverage of immunosuppression ends and how that nonadherence impacts allograft histology. The goal of this study was to compare rates of nonadherence during posttransplant years 1 to 3 to years 3 to 5 and examine the relationship between nonadherence during years 3 to 5 and 5-year allograft histology. Methods We retrospectively analyzed 552 conventional kidney allografts in patients transplanted at our center between January 1, 1999, and June 1, 2010, who used the Mayo Clinic Specialty Pharmacy for the first 5 years posttransplant. Nonadherence was defined as less than 80% proportion of days covered. Overall adherence to immunosuppression appeared to be higher during years 3 and 5 compared to between years 1 and 3 (89.4% vs 82.9%, respectively; P < 0.0001 [paired t test]). Results Overall nonadherence during posttransplant years 3 to 5 appeared to be associated with fibrosis and inflammation on 5-year allograft biopsy but not with transplant glomerulopathy (16.9% vs 5.9%, P = 0.004; 10.4% vs 8.5%, P = 0.61, respectively). After adjusting for nonadherence to calcineurin inhibitor and prednisone therapy, only nonadherence to antimetabolite therapy remained significantly associated with 5-year fibrosis and inflammation (odds ratio, 10.6; 95% confidence interval, 1.5-76.1; P = 0.02). Conclusions Efforts to improve long-term adherence, possibly through the use of specialty pharmacies and increased adherence to antimetabolite therapy, may improve long-term allograft histology and survival, although further studies are needed to confirm these findings.
Thoracogenic spinal deformity: a rare cause of early-onset scoliosis
Eby, Sarah F. , Hilaire, Tricia St., Glotzbecker, Michael P. , Smith, John T. , White, Klane K. , _, _, Larson, A. Noelle , _, _

Mayo Clinic

Journal of Neurosurgery: Spine | September 7, 2018 | Volume: 29 | Issue: 6 | Pages: 674-679

10.3171/2018.4.spine171389 | PMID 30192221 Get It

OBJECTIVESurgery for severe congenital defects, such as congenital diaphragmatic hernia, congenital heart defects, and tracheoesophageal disorders, are life-saving treatments for many infants. However, the incidence of scoliosis following thoracoabdominal surgery has been reported to range from 8% to 50%. Little is known about severe scoliosis that occurs after chest wall procedures in infants. The authors sought to determine the prevalence of thoracogenic scoliosis, disease severity, and need for scoliosis surgery in patients who underwent chest wall procedures in early childhood.METHODSA multicenter database of patients with early-onset scoliosis was queried to identify patients with a history of thoracogenic or acquired iatrogenic scoliosis. Patients with significant congenital spine deformities were excluded. Forty-one patients (1.6%) were noted to have thoracogenic scoliosis. Of these patients, 14 patients were observed; 10 received casts and/or braces; and 17 underwent treatment with rib-based distraction rods, Shilla procedures, or spine-based growing rod devices. Radiographs, complications, and patient characteristics were reviewed.RESULTSThe mean age at scoliosis diagnosis for the 41 patients was 6.0 years. The mean time to follow-up was 2.9 years (4.5 years in the 17 surgical patients). The mean preoperative coronal Cobb angle in the surgical group was 65° and improved to 47° postoperatively (p = 0.01). The mean Cobb angle for the nonoperative group was 31° initially and 32° at follow-up (p = 0.44). Among the 17 patients undergoing surgery for scoliosis, there were 13 complications in 7 patients, including a brachial plexus palsy following rib-based distraction rod placement. This resolved with revision of the rib hooks. There were no known complications in the nonoperative cohort.CONCLUSIONSSevere scoliosis can develop after thoracoabdominal surgeries during infancy. Further work is needed to understand the pathogenesis of scoliosis in this population so as to implement measures for prevention and early diagnosis and to guide appropriate treatment.
Biomechanical Evaluation of Suture Anchor versus Transosseous Tunnel Patellar Tendon Repair Techniques
Sherman, Seth L. , Black, Brandee S., Mooberry, Matthew A., Freeman, Katie L., Gulbrandsen, Trevor R. , Milles, Jeffrey L., Evans, Laura , Flood, David, Mooberry, Matthew, Evans, Laura, Pfeiffer, Ferris M.

Mayo Clinic

The Journal of Knee Surgery | September 6, 2018 | Volume: 32 | Issue: 08 | Pages: 825-832

10.1055/s-0038-1669790 | PMID 30189438 Get It

Abstract The objective of this study is to compare the cyclic loading strength and ultimate failure load in suture anchor repair versus transosseous tunnel repair of patellar tendons using a cadaver model. Twelve cadaveric patella specimens were used (six matched pairs). Dual-energy X-ray absorptiometry (DXA) measurements were performed to ensure equal bone quality among groups. All right knees were assigned to the suture anchor repair group (n = 6), whereas all left knees were assigned to the transosseous bone tunnel group (n = 6). Suture type and repair configuration were equivalent. After the respective procedures were performed, each patella was mounted into a gripping jig. Tensile load was applied at a rate of 1 Hz between magnitudes of 50 and 150 N, 50 and 200 N, 50 and 250 N, and tensile load at a rate of 0.1 mm/s until failure. Failure was defined as a sharp deviation in the linear load versus displacement curve, and failure mode was recorded. DXA measurements demonstrated equivalence of bone quality between the two groups (p > 0.05). During cyclic load testing, there was only a statistically significant difference between the groups with regard to cyclic loading at the 50 to 200 N loading cycle (p = 0.010). There was no statistically significant difference between the groups with regard to ultimate load to failure (p = 0.43). Failure mode within the suture anchor cohort occurred through anchor pullout except for one, which failed through the tendon. All specimens within the transosseous cohort failed through the midsubstance of the tendon except for one, which failed through suture breakage. Suture anchor repair demonstrated a similar biomechanical profile regarding cyclic loading and ultimate load to failure when compared with “gold standard” transosseous tunnel patellar tendon repair with a trend toward less gapping in the suture anchor group. Using suture anchors for repair of the patella tendon has similar biomechanical properties to transpatellar tunnels but may provide other clinical advantages.
Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.
Litzow, Mark R. , Perl, Alexander E. , Altman, Jessica K. , Gill, Stan, Yuen, Geoffrey J., Bonate, Peter L. , Kadokura, Takeshi , James, Angela , Nagase, Itsuro, Fisniku, Ogert, Bahceci, Erkut, Smith, Catherine C. , Levis, Mark J. , Liu, Charles

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7026-7026

10.1200/jco.2016.34.15_suppl.7026 Get It

E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process.
Weinstein, Gregory S., Mehra, Ranee , García, Joaquín J. , Chung, Christine H. , Gillison, Maura L. , Ringash, Jolie , Méndez, Eduardo, Richmon, Jeremy D. , Magnuson, Scott, Smith, Russel B., Thomas, Giovana R. , Richmon, Jeremy D , Li, Shuli , Ferris, Robert L. , Holsinger, F. Christopher , Quon, Harry , Wagner, Lynne I. , Lewin, Jan S. , Ridge, John Andrew , Bell, R. Bryan , Burtness, Barbara

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 6054-6054

10.1200/jco.2016.34.15_suppl.6054 Get It

First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.
Beg, Muhammad Shaalan , Sachdev, Jasgit C. , Lim, Ho Yeong , Kim, Tae‐You, Becerra, Carlos, Bader, Andreas G. , Stoudemire, Jay, Smith, Susan, Kim, Sinil, Hong, David S. , Brenner, Andrew Jacob , Borad, Mitesh J. , Park, Keunchil , Smith, Susan, Kang, Yoon‐Koo

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS2597-TPS2597

10.1200/jco.2016.34.15_suppl.tps2597 Get It

A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).
Demeure, Michael J. , Armaghany, Tannaz , Ejadi, Samuel, Ramanathan, Ramesh K., Elfiky, Aymen, Smith, David C. , Sekar, Shobana , Carpten, John D. , Fredlund, Paul, Niforos, Demi, Dye, Andrew, Gahir, Sarabjit, Semple, Sean C., Kowalski, Mark , Strosberg, Jonathan , Whitsett, Timothy G. , Liang, Winnie S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2547-2547

10.1200/jco.2016.34.15_suppl.2547 Get It

MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.
Sachdev, Jasgit C. , Ejadi, Samuel, Kim, Tae‐You, Lim, Ho Yeong , Becerra, Carlos, Bader, Andreas G. , Stoudemire, Jay, Smith, Susan, Kim, Sinil, Beg, Muhammad Shaalan , Hong, David S. , Kang, Yoon‐Koo , Brenner, Andrew Jacob , Borad, Mitesh J. , Park, Keunchil , Smith, Susan

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2508-2508

10.1200/jco.2016.34.15_suppl.2508 Get It

ADVL1522: A phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), and sy
Kudgus, Rachel A. , Schoon, Renee A., McGovern, Renee M., Cajaiba, Mariana M. , Barkauskas, Donald A. , Dome, Jeffrey S. , Fox, Elizabeth , Weigel, Brenda J. , Geller, James I. , Pressey, Joseph G. , Smith, Malcolm A. , Reid, Joel M. , Hall, David

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 10537-10537

10.1200/jco.2017.35.15_suppl.10537 Get It

10537 Background: Lorvotuzumab mertansine (IMGN901; LM) is an antibody-drug conjugate, linking anti-mitotic agent (DM1) to an anti-CD56 antibody. Preclinical data show effects in Wilms tumor (WT), rhabdomyosarcoma (RMS), and neuroblastoma (NBL). Synovial sarcoma (SS), MPNST and pleuropulmonary blastoma (PPB) also express CD56. A phase 2 trial assessing the efficacy and tolerability of LM administered at the adult recommended phase 2 dose (RP2D) was conducted in children with relapsed tumors. Methods: LM (110 mg/m2/dose) was administered IV on days (d) 1 and 8 of 21 d cycles, with dexamethasone pre-medication. The tolerability of LM was assessed in 6 patients prior to trial activation group-wide. Dose limiting toxicity (DLT) was assessed using CTCAE. Response was assessed by RECIST. Pharmacokinetics (PK) were obtained during cycle 1. Peripheral blood CD56-positive cells were measured d1 and d8 pre-dose. Tumor CD56 expression by immunohistochemistry in archival tissue was scored (0-3+). Results: Sixty-two patients were enrolled. The median (range) age was 14.3 y (2.8–29.9); 35 were male. Diagnoses included WT (17), RMS (17), NBL (12), SS (10), MPNST (5) and PPB (1). One patient was ineligible due to lack of measurable disease. Of 61 eligible patients, 47 were evaluable for toxicity, 50 for response, 50 for tumor CD56 expression; and 18 consented to optional PK. Five patients experienced 9 DLTs: hyperglycemia (1), colonic fistula (1) with perforation (1), nausea (1) with vomiting (1), increased ALT (2 in cycle 1; 1 in cycle 2 with increased AST (1)). Non-dose limiting toxicities (Grade ≥3) attributed to LM included lymphopenia, anemia, vomiting, dehydration, hypokalemia, hyperuricemia, hypophosphatemia. Mean DM1 Cmax, t1/2 and AUC0-∞values were 922 ng/ml, 33 h and 27400 ng/ml*h, respectively. Tumor CD56 expression was 0 (8%), 1+(4%), 2+(12%), 3+(76%). LM and CD56 antibody PK, and response, will be reported. Conclusions: LM (110 mg/m2) is tolerated in children at the adult RP2D. Clinical trial information: NCT 02452554.